P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847720.26592.b6 |
| _version_ | 1797285936842670080 |
|---|---|
| author | M. R. Clausen F. Offner D. Belada J. Brody K. M. Linton Y. Karimi R. Cordoba S. Snauwaert A. Abbas L. Wang J. Wu B. Elliott L. Falchi |
| author_facet | M. R. Clausen F. Offner D. Belada J. Brody K. M. Linton Y. Karimi R. Cordoba S. Snauwaert A. Abbas L. Wang J. Wu B. Elliott L. Falchi |
| author_sort | M. R. Clausen |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:21Z |
| format | Article |
| id | doaj.art-7308de27081b4dd0a72c2681769528f0 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:21Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-7308de27081b4dd0a72c2681769528f02024-03-02T07:47:22ZengWileyHemaSphere2572-92412022-06-0161100110110.1097/01.HS9.0000847720.26592.b6202206003-01100P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATEM. R. Clausen0F. Offner1D. Belada2J. Brody3K. M. Linton4Y. Karimi5R. Cordoba6S. Snauwaert7A. Abbas8L. Wang9J. Wu10B. Elliott11L. Falchi121 Vejle Hospital, Vejle, Denmark2 Universitair Ziekenhuis Gent, Ghent, Belgium3 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czechia4 Icahn School of Medicine at Mount Sinai, New York, United States of America5 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom6 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States of America7 Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain8 Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium9 Genmab, Princeton9 Genmab, Princeton10 AbbVie, North Chicago9 Genmab, Princeton11 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847720.26592.b6 |
| spellingShingle | M. R. Clausen F. Offner D. Belada J. Brody K. M. Linton Y. Karimi R. Cordoba S. Snauwaert A. Abbas L. Wang J. Wu B. Elliott L. Falchi P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE HemaSphere |
| title | P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE |
| title_full | P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE |
| title_fullStr | P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE |
| title_full_unstemmed | P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE |
| title_short | P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE |
| title_sort | p1214 subcutaneous epcoritamab r chop for first line treatment of patients with high risk diffuse large b cell lymphoma phase 1 2 update |
| url | http://journals.lww.com/10.1097/01.HS9.0000847720.26592.b6 |
| work_keys_str_mv | AT mrclausen p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT foffner p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT dbelada p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT jbrody p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT kmlinton p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT ykarimi p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT rcordoba p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT ssnauwaert p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT aabbas p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT lwang p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT jwu p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT belliott p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update AT lfalchi p1214subcutaneousepcoritamabrchopforfirstlinetreatmentofpatientswithhighriskdiffuselargebcelllymphomaphase12update |